drugset / Trial / NCT02470403

Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index

NCT02470403

Phase 2 Completed 181 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindOther

Summary

A 12-week study to assess LIK066 effect on body weight in diabetics, prediabetics and normoglycemic patients with elevated body mass index (BMI)

Timeline

Start
2015-06-05
Primary completion
2016-04-04
Completion
2016-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject licogliflozin Small molecule 50 mg
Subject licogliflozin Small molecule 75 mg
Subject licogliflozin Small molecule 150 mg

Indications